{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:41:40Z","timestamp":1791423700352,"version":"4.3.3"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:00:00Z","timestamp":1520899200000},"content-version":"vor","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB\/TRR79"],"award-info":[{"award-number":["SFB\/TRR79"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD13\/00340"],"award-info":[{"award-number":["CD13\/00340"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["GCB120981SAN"],"award-info":[{"award-number":["GCB120981SAN"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ccell.2017.02.002","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T14:28:52Z","timestamp":1488464932000},"page":"396-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":296,"title":["Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment"],"prefix":"10.1016","volume":"31","author":[{"given":"Anja","family":"Seckinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Neuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Lipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Prosper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Emde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Delon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Latzko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Gianotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"L\u00fcoend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Murr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Hosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia Jasmin","family":"Harnisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Bacac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Fauti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aintzane","family":"Zabaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta Ada","family":"Cavalcanti-Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus F.","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Strein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Uma\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh Diem","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2017.02.002_bib1","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.02.002_bib2","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-15-1696","article-title":"A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors","volume":"22","author":"Bacac","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2017.02.002_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","article-title":"Novel immunotherapies in lymphoid malignancies","volume":"13","author":"Batlevi","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2017.02.002_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-3-540-85772-3_2","article-title":"Epidemiology of multiple myeloma","volume":"183","author":"Becker","year":"2011","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.ccell.2017.02.002_bib5","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2004-11-4463","article-title":"Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor","volume":"105","author":"Bellucci","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.02.002_bib6","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.molimm.2005.07.034","article-title":"MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors","volume":"43","author":"Brischwein","year":"2006","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ccell.2017.02.002_bib7","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T\u00a0cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2017.02.002_bib8","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2017.02.002_bib9","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2002-01-0008","article-title":"A molecular compendium of genes expressed in multiple myeloma","volume":"100","author":"Claudio","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.02.002_bib10","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2017.02.002_bib11","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.4049\/jimmunol.1200341","article-title":"Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T\u00a0cells","volume":"189","author":"Feldmann","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2017.02.002_bib12","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T\u00a0cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.02.002_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","article-title":"Mode of cytotoxic action of T\u00a0cell-engaging BiTE antibody MT110","volume":"214","author":"Haas","year":"2009","journal-title":"Immunobiology"},{"key":"10.1016\/j.ccell.2017.02.002_bib14","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood.V126.23.2999.2999","article-title":"BI 836909, a novel bispecific T\u00a0cell engager for the treatment of multiple myeloma induces highly specific and efficacious lysis of multiple myeloma cells in\u00a0vitro and shows anti-tumor activity in\u00a0vivo","volume":"126","author":"Hipp","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.02.002_bib15","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2008-09-178350","article-title":"Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma","volume":"113","author":"Hose","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.02.002_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma","volume":"96","author":"Hose","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.ccell.2017.02.002_bib17","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl Med."},{"key":"10.1016\/j.ccell.2017.02.002_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm.4015","article-title":"Prospects for gene-engineered T\u00a0cell immunotherapy for solid cancers","volume":"22","author":"Klebanoff","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2017.02.002_bib19","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.02.002_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2014.08.003","article-title":"Bispecific antibody platforms for cancer immunotherapy","volume":"92","author":"Lameris","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ccell.2017.02.002_bib21","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.02.002_bib22","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.02.002_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1359-6101(03)00023-6","article-title":"The TNF family members BAFF and APRIL: the growing complexity","volume":"14","author":"Mackay","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ccell.2017.02.002_bib24","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.02.002_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0609.2009.01262.x","article-title":"APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop","volume":"83","author":"Moreaux","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ccell.2017.02.002_bib26","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in Smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2017.02.002_bib27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells","volume":"173","author":"Ng","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2017.02.002_bib28","first-page":"477","article-title":"Expression levels of CD38 and complement inhibitory proteins CD55 and CD59 predcit response to daratumumab in multiple myeloma","volume":"100","author":"Nijhof","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ccell.2017.02.002_bib29","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.02.002_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2017.02.002_bib31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive strategies that are mediated by tumor cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ccell.2017.02.002_bib32","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1021\/jacs.5b01876","article-title":"An anti-B cell maturation antigen bispecific antibody for multiple myeloma","volume":"137","author":"Ramadoss","year":"2015","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ccell.2017.02.002_bib33","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T\u00a0cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2017.02.002_bib34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"key":"10.1016\/j.ccell.2017.02.002_bib35","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2017.02.002_bib36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ccell.2015.08.009","article-title":"Engineering anti-myeloma responses using affinity-enhanced TCR-engineered T\u00a0cells","volume":"28","author":"San Miguel","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2017.02.002_bib37","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2017.02.002_bib38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ccell.2017.02.002_bib39","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1038\/onc.2009.257","article-title":"Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis","volume":"28","author":"Seckinger","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ccell.2017.02.002_bib40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/314628a0","article-title":"Hybrid antibodies can target sites for attack by T\u00a0cells","volume":"314","author":"Staerz","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2017.02.002_bib41","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.02.002_bib42","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2017.02.002_bib43","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610817300168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610817300168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:58:36Z","timestamp":1761523116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610817300168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1535610817300168"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2017.02.002","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2017.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2017.02.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2017.02.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}